• Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

  NCT05195710

  RecruitingInterventionalPhase 1Updated May 26, 2026
• Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

  NCT04668872

  RecruitingObservationalUpdated Mar 12, 2026
• Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

  NCT04108481

  TerminatedInterventionalPhase 1Updated Mar 28, 2025
• Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer

  NCT03307603

  WithdrawnInterventionalPhase 1Phase 2Updated Feb 27, 2018
• Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer

  NCT03028311

  Active, not recruitingInterventionalPhase 1Updated Mar 10, 2026
• A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver

  NCT01098422

  TerminatedInterventionalNot ApplicableUpdated Aug 24, 2021

ClinicalTrials.gov ID

NCT07406126

Lead Sponsor

Fernando Gómez MuñozOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

30Estimated

Last Update Posted

Feb 12, 2026Actual

Start Date

Feb 2026Estimated

Primary Completion Date

Jul 2028Estimated

Completion Date

Jul 2028Estimated

Official Title

Y90 Radioembolization as Neoadjuvant Therapy for Potentially Resectable Patients With Colorectal Liver Metastases: Immune Markers Evaluation, Impact on Circulating Tumor DNA and Personalized Dosimetry Approach

Brief Summary

This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in clinical practice for potentially resectable patients with colorectal liver metastases (CRLM). Alternatively, resectability will also be evaluated. The investigators hypothesize that by applying this approach, higher local control and resection rates can be achieved (typically below 13% for patients who are initially deemed unresectable). Additionally, this treatment option is expected to help delay or reduce the need for (a switch in) systemic treatment and eventually improve survival in patients with liver metastases that are not resectable. All studies reporting the results of TARE at ablative doses are retrospective cohort studies or cases series. Prospective data is needed to expand the indications and reimbursement of radioembolization.

Other objectives of the study are:

• To calculate the resection rate in patients undergoing the combined approach.
• To evaluate immune markers in peripheral blood and resected metastases.
• To formulate the first concept of an algorithm, enable to deliver personalized AI assisted dosimetry.
• To assess potential role of circulating tumor DNA (ctDNA) in evaluation of patient prognosis and follow up.
• To determine the grade of necrosis at the time of resection and correlate with the absorbed dose.

• Colorectal Liver Metastases (CRCLM)
• Unresectable Colorectal Liver Metastases

• Yttrium-90 Radioembolization with standard systemic therapy

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Histologically confirmed primary adenocarcinoma of the colon or rectum

• Potentially resectable colorectal liver metastases, with limiting factors for resection including:

  1. Insufficient future liver remnant.
  2. Unfavorable tumor location (e.g. involvement of a major vessel and/or bile duct)/ large size and/ or number of lesions, which limit resection with R0 margins and requires downsizing of the metastases

• No or limited extrahepatic metastatic disease (limited extrahepatic disease should be amenable to eradicate with locoregional therapies as per multidisciplinary discussion of surgeons, radiation oncologists and interventional radiologists)

• Patient should match standard 90Y radioembolization inclusion criteria:

  1. Signed informed consent;
  2. Age ≥ 18 years;
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
  4. Life expectancy of ≥ 3 months;
  5. Measurable target tumors in the liver according to RECIST 1.1

• Laboratory parameters: eGFR >45/mL/min/1.73 m2; albumin > 3.0 g/dl, normal bilirubin (unless Gilbert syndrome); aminotransferase (ALAT/ASAT) <3.0 ULN

Exclusion Criteria:

• Life expectancy ≤3 months
• Patient initially eligible for surgery or thermal ablation of the liver metastases
• Progressive extra-hepatic disease
• Active extra-hepatic disease that cannot be treated
• Life-threatening extra-hepatic disease (i.e. dialysis, unresolved diarrhea, serious unresolved infections (HIV, HBV, HCV etc.))
• Uncorrectable coagulopathy
• Contraindication for angiography or MRI
• Significant toxicities due to prior cancer therapy that have not resolved before the initiation of the study; if the investigator determines that the continuing complication will compromise the safe treatment of the patient
• Any surgical contraindication
• Ascites
• Expected difficulties for safe execution of TARE based on pretreatment Tc99m-MAA imaging, including;
• Flow to extra-hepatic vessels not correctable by reposition of catheter or embolization Uncorrectable estimated dose to the lungs >30Gy in a single administration or >50Gy cumulatively
• Uncorrectable estimated dose to the untreated liver of >70Gy
• Estimated average dose to the viable tumor volume <200Gy
• Prior liver radiotherapy
• Severe portal hypertension
• Second primary malignancy within the past 5 years, other that adequately treated non-melanoma skin cancer, carcinoma in situ of any organ or second primary colorectal cancer
• Unresectable primary tumor in situ;
• Other serious comorbidity or any other condition, that renders patients unsuitable for the study treatment
• Pregnancy, lactation or refusal to use adequate contraceptive measures
• History of allergic reaction to any components of the treatment that cannot be medically corrected.

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Fernando Gómez MuñozOTHER

Collaborators

Instituto de Investigacion Sanitaria La FeOTHER

Boston Scientific International S.A.UNKNOWN

jorgemolinasaera@gmail.com

antonio.rodriguez.fernandez.sspa@juntadeandalucia.es

gomez_fermun@gva.es